About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« From Each According To Their Creativity, To Each According To Their Difficulty? | Main | Ricin Redux »

February 1, 2004

Deal Me In

Email This Entry

Posted by Derek

The inventor of the blue-light diode, Shuji Nakamura, has been fighting for some years now for a bigger piece of the profits from his invention. Since his original payment was about US $189, that's easy to imagine. The New York Times article on the case is fine, as far as it goes, but it contains one very puzzling paragraph:

On patent filings, Japanese companies list their names above the inventor's; Western companies typically file patents on behalf of their employees and pay them a percentage of the profits.

My readers around the drug industry are all going "Since @#$!*! when?" I can tell you that all you get at a large pharma company is a hearty handshake. Oh, if your drug does make it to market, it's certainly good for your career, true. But a percentage of the profits? Not in the US. But there are places.

Take Germany, for example. Under German law, inventions produced by employees of corporations are still their property, which is transferred to the company in exchange for specific payment. There are all sorts of situations that arise from this (the link above will take you through them) but the result in the drug industry is that the inventors on a patent get a share of the profits from the marketed drug. Interestingly, a similar law has been proposed in the UK, and is now being debated.

This sets up some major struggles about inventorship, as you'd imagine. I'm told there have been some real brawls over the years. In a US drug company, being an inventor on a patent is quite desirable. But in Germany, it can change your life.

As someone who's been an inventor on many issued patents, I can tell you that I'd certainly support such a system in the US. There's a real case to be made for it, and not just by folks who could profit (hey, none of my patents has ever made a dime for anyone.) Over on The Bottom Line, fellow Corantean Arnold Kling has commented on the patent idea that was discussed in the post below (which he'd also noticed, just before I did.) He proposes a greater use of prizes as an incentive to innovation, which I think is a fine idea. A piece of the action would be a good start.

Comments (0) + TrackBacks (0) | Category:



Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry